Covid-19 roundup: J&J part­ners with Catal­ent on 1B dose vac­cine goal; BioN­Tech, Pfiz­er be­gin mR­NA vac­cine tri­al in Ger­many

Sec­ond on­ly to the ques­tion of how you make a vac­cine work is how you make enough of them to match the im­me­di­ate glob­al de­mand any ap­proved prod­uct in­oc­u­la­tion will face.

BAR­DA has put mil­lions be­hind man­u­fac­tur­ing Mod­er­na’s can­di­date. Ox­ford has a large part­ner in In­dia. Cure­Vac has its own fac­to­ries and fund­ing to ex­pand. Sanofi is retro­fitting ex­ist­ing fa­cil­i­ties. Now J&J has un­veiled part of their man­u­fac­tur­ing an­swer, sign­ing a col­lab­o­ra­tion with Catal­ent, one of the largest bi­o­log­ics man­u­fac­tur­ers in the world.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.